[Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1, hyaluronic acid and antibodies against cyclic citrullinated peptide in Lyme arthritis, rheumatoid arthritis and patients with arthritic complaints].
Level 4 - case-series / case-control
Cross-sectional comparative study assessing diagnostic biomarkers
What was done
The authors evaluated serum levels of matrix metalloproteinases (MMP-3, MMP-9), tissue inhibitor of metalloproteinases 1 (TIMP-1), hyaluronic acid (HA), and anti-cyclic citrullinated peptide (anti-CCP) antibodies across three clinical groups: patients with Lyme arthritis, patients with rheumatoid arthritis (RA), and patients with general arthritic complaints.
What was found
The abstract reports no numerical values. Plasma levels of MMP-3, HA, and anti-CCP were reported as significantly higher in the rheumatoid arthritis group compared to the Lyme arthritis group and patients with arthritic complaints. No significant differences in MMP-3, MMP-9, TIMP-1, HA, or anti-CCP were observed between patients with Lyme arthritis and those with general arthritic complaints.
Why it matters
These serum biomarkers are not clinically useful for distinguishing Lyme arthritis from non-specific arthritic symptoms, though elevated MMP-3, HA, and anti-CCP help differentiate rheumatoid arthritis from Lyme arthritis.
Limits
The abstract does not provide sample sizes, baseline patient characteristics, exact assay methods, quantitative concentrations, or test performance characteristics (sensitivity, specificity, or predictive values).
Cited by
- partial Matrix metalloproteinases (MMPs) are elevated when Lyme disease affects the joints.